Strategy
Stages
SeedVentureGrowthCrossover
Sectors
HealthcareBiotechPlanetary Health
Geographies
USABoston, Massachusetts, USA
Check size
$5M-$100MRecent changes
- Sep 6, 2026Sep 6, 2026Sectors updated: Healthcare, Biotech, Planetary Health racap.com
- Sep 6, 2026Sep 6, 2026Stages updated: Seed, Venture, Growth, Crossover racap.com
- Jul 2, 2026Jul 2, 2026Invested in Celea Therapeutics ($180M) Celea Therapeutics
Portfolio
2 totalRecent Investment Activity
1| Date | Company | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|
| Jul 2, 2026 | Celea Therapeutics | funding round | $180M | — | outlined = lead | Celea Therapeutics |
Co-Investors
9Latest Pulse
- Sep 9, 2026Solstice Oncology Launches With $225M Series ASolstice Oncology launched with a $225 million Series A led by RA Capital Management to advance porustobart, a second-generation CTLA-4 immunotherapy licensed from Harbour BioMed, into two Phase 2 cancer trials.→
- Aug 27, 2026AusperBio Raises $120M for Hepatitis B CureAusperBio Therapeutics raised a $120 million Series C led by a strategic investor with RA Capital joining, bringing total funding to $360 million as its lead hepatitis B therapy enters Phase 3.→
- Jul 2, 2026Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis DrugCelea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed.→
Sources & methodologyshow
Where these figures come from
- Celea Therapeuticsprimary source1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.